Veracyte, Inc.

VCYT

Healthcare

$41.23+25.05%vs prev close

$22.61

$50.71

52W Range

+8.91 (+27.57%)Past 1M

Price

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

2,692,949

Portfolio Weight

0.7%

in ETF 2.65%

Est. Value

$90M

30D Net

-$162K

Ray DalioBridgewater Associates

New Buy

28,394

Portfolio Weight

Est. Value

$1M

Change

New position

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Analyst Targets

avg.

$46.55

vs Current ▲ +12.9% upside

Current$41.23

Low ~ High$37.00 ~ $53.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Canaccord Genuity

Hold

$40.00

-2.98%

$33.45

Maintain

2026-04-20

Jefferies

Buy

$45.00

+9.14%

$32.44

Upgrade

2026-04-13

Needham

Buy

$48.00

+16.42%

$32.40

Maintain

2026-04-01

Guggenheim

Buy

$45.00

+9.14%

$30.44

Maintain

2026-03-30

Morgan Stanley

Underweight

$37.00

-10.26%

$33.85

Maintain

2026-03-06

1 / 21

Avg Target

$46.55

vs Current ▲ +12.9% upside

Buy

12 analysts

Strong Buy 1Buy 9Hold 1Sell 1

Low $37.00

Current $41.23

High $53.00

Firm	Position	Target	Upside	Close	Action	Date
Canaccord Genuity	Hold	$40.00	-2.98%	$33.45	Maintain	26.04.20
Jefferies	Buy	$45.00	+9.14%	$32.44	Upgrade	26.04.13
Needham	Buy	$48.00	+16.42%	$32.40	Maintain	26.04.01
Guggenheim	Buy	$45.00	+9.14%	$30.44	Maintain	26.03.30
Morgan Stanley	Underweight	$37.00	-10.26%	$33.85	Maintain	26.03.06

1 / 21

Price Information

Previous Close$32.97

Open$38.69

Day Range$35.54 - $41.66

52-Week Range$22.61 - $50.71

1-Year Change6.91%

Trading Volume

Volume2,042,059

Avg Volume (3mo)892,525

Valuation

Market Cap3.3B

Book Value$16.50

Shares Outstanding79,792,167

Financials

Revenue (TTM)517.1M

Net Income66.4M

EPS$1.08

EBITDA84.4M

Profitability

P/E Ratio38.18

P/B Ratio2.50

Return on Equity (ROE)5.34%

Return on Assets (ROA)2.91%

Profit Margin12.83%

EV/EBITDA26.62

Beta1.89

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)75.50

Company Overview

Veracyte, Inc. is a global diagnostics company that provides genomic tests to help diagnose cancer. Their main products include genomic classifiers for thyroid, prostate, bladder, and lung cancers, as well as a breast cancer assay. Veracyte aims to improve patient care by offering precise diagnostic solutions.

P/B

2.50

Price-to-Book

ROE

5.3%

Low return

Beta

1.89

High volatility

RSI(14)

75.5

Overbought

AI-generated summary. Not investment advice.